

Sao Tome and Principe

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–0.013)	3.6 (1.4–6.9)
Mortality (HIV+TB only)	<0.01 (0–0.015)	1.3 (0–8)
Incidence (includes HIV+TB)	0.18 (0.18–0.19)	97 (94–100)
Incidence (HIV+TB only)	0.028 (0.018–0.041)	15 (9.7–21)
Incidence (MDR/RR-TB)**	0.036 (0.026–0.046)	19 (14–24)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.012 (<0.01–0.016)	0.056 (0.042–0.07)	0.068 (0.05–0.086)
Males	<0.01 (<0.01–0.01)	0.11 (0.088–0.13)	0.12 (0.092–0.14)
Total	0.019 (0.014–0.024)	0.17 (0.16–0.17)	0.18 (0.18–0.19)

TB case notifications, 2015

Total cases notified	207
Total new and relapse	178
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	89%
- % bacteriologically confirmed among pulmonary	38%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	96% (93–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.01–0.12)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	24	13%
- on antiretroviral therapy	24	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			38 (28–49)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	88% (47–100)	
% notified tested for rifampicin resistance	1%	69%	29
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	74%	149
Previously treated cases, excluding relapse, registered in 2014	56%	9
HIV-positive TB cases, all types, registered in 2014	54%	24
MDR/RR-TB cases started on second-line treatment in 2013	83%	6
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	4%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	<1
Funding source: 1% domestic, 75% international, 24% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically